A Polymorphism in the Resistin Gene Promoter is Related to Increased C-reactive Protein Levels in Patients with Coronary Artery Disease.

Na-Ping Tang,Lian-Sheng Wang,Li Yang,Bo Zhou,Hai-Juan Gu,Qing-Min Sun,Ri-Hong Cong,Huai-Jun Zhu,Bin Wang

DOI: https://doi.org/10.1515/cclm.2007.308

2007-01-01

Clinical Chemistry and Laboratory Medicine (CCLM)

Abstract:BACKGROUND Resistin, a novel adipocyte-derived peptide, has been linked to inflammatory process and coronary artery disease (CAD). The -420C>G polymorphism located in the resistin gene (RETN) promoter has recently been suggested to play a potential role in proinflammatory conditions (e.g., atherogenesis). However, whether this polymorphism has any effect on the inflammatory process in patients with stable CAD is unclear. METHODS The RETN -420C>G polymorphism was determined by using PCR-restriction fragment length polymorphism. Plasma lipid profiles, glucose and high-sensitivity C-reactive protein (hs-CRP) were measured in fasting state. RESULTS Patients with variant genotypes (CG+GG) had significantly higher levels of hs-CRP than CC carriers (adjusted p<0.001). In addition, the variant genotypes were observed to be independently associated with higher hs-CRP levels (>3 mg/L, p=0.004). However, no association was found between this polymorphism and plasma lipids or glucose levels. CONCLUSION Our data suggest that the RETN -420C-to-G variant is associated with increased CRP levels in patients with stable CAD, suggesting that the RETN -420C>G polymorphism may be potentially involved in the inflammatory component of atherogenesis through an enhanced production of CRP.